ASCO 2026 | What are the key determinants of cancer-related cognitive impairment?

Filippos Koinis • 1 Jun 2026

ASCO 2026

General

Filippos Koinis, MD, PhD, University of Thessaly, Larissa, Greece, discusses the key drivers of cancer-related cognitive impairment (CRCI), including genetic predisposition, cancer itself, and treatment-related factors such as chemotherapy, which can have direct neurotoxic effects on the brain. While certain patient groups, such as older patients and those with pre-existing dementia or anxiety disorders, are at higher risk of developing CRCI, cognitive assessment tools should be implemented broadly as CRCI is not confined to these groups. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.